# EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

> **NCT05127525** · PHASE3 · TERMINATED · sponsor: **iRenix Medical, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Diabetic Macular Edema
- Branch Retinal Vein Occlusion
- Glaucoma/Closed Angle Glaucoma

## Interventions

- **DRUG:** IRX-101
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT05127525
- **Lead sponsor:** iRenix Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-15
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Adverse event
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05127525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05127525, "EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05127525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*